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Abstract
Glucose-6-phosphatase deficiency (G6P deficiency), or glycogen storage disease type I (GSDI), is a group of inherited
metabolic diseases, including types Ia and Ib, characterized by poor tolerance to fasting, growth retardation and
hepatomegaly resulting from accumulation of glycogen and fat in the liver. Prevalence is unknown and annual
incidence is around 1/100,000 births. GSDIa is the more frequent type, representing about 80% of GSDI patients. The
disease commonly manifests, between the ages of 3 to 4 months by symptoms of hypoglycemia (tremors, seizures,
cyanosis, apnea). Patients have poor tolerance to fasting, marked hepatomegaly, growth retardation (small stature
and delayed puberty), generally improved by an appropriate diet, osteopenia and sometimes osteoporosis,
full-cheeked round face, enlarged kydneys and platelet dysfunctions leading to frequent epistaxis. In addition, in
GSDIb, neutropenia and neutrophil dysfunction are responsible for tendency towards infections, relapsing aphtous
gingivostomatitis, and inflammatory bowel disease. Late complications are hepatic (adenomas with rare but possible
transformation into hepatocarcinoma) and renal (glomerular hyperfiltration leading to proteinuria and sometimes to
renal insufficiency). GSDI is caused by a dysfunction in the G6P system, a key step in the regulation of glycemia. The
deficit concerns the catalytic subunit G6P-alpha (type Ia) which is restricted to expression in the liver, kidney and
intestine, or the ubiquitously expressed G6P transporter (type Ib). Mutations in the genes G6PC (17q21) and SLC37A4
(11q23) respectively cause GSDIa and Ib. Many mutations have been identified in both genes,. Transmission is
autosomal recessive. Diagnosis is based on clinical presentation, on abnormal basal values and absence of
hyperglycemic response to glucagon. It can be confirmed by demonstrating a deficient activity of a G6P system
component in a liver biopsy. To date, the diagnosis is most commonly confirmed by G6PC (GSDIa) or SLC37A4
(GSDIb) gene analysis, and the indications of liver biopsy to measure G6P activity are getting rarer and rarer.
Differential diagnoses include the other GSDs, in particular type III (see this term). However, in GSDIII, glycemia and
lactacidemia are high after a meal and low after a fast period (often with a later occurrence than that of type I).
Primary liver tumors and Pepper syndrome (hepatic metastases of neuroblastoma) may be evoked but are easily
ruled out through clinical and ultrasound data. Antenatal diagnosis is possible through molecular analysis of
amniocytes or chorionic villous cells. Pre-implantatory genetic diagnosis may also be discussed. Genetic counseling
should be offered to patients and their families. The dietary treatment aims at avoiding hypoglycemia (frequent
meals, nocturnal enteral feeding through a nasogastric tube, and later oral addition of uncooked starch) and acidosis
(restricted fructose and galactose intake). Liver transplantation, performed on the basis of poor metabolic control
and/or hepatocarcinoma, corrects hypoglycemia, but renal involvement may continue to progress and neutropenia
is not always corrected in type Ib. Kidney transplantation can be performed in case of severe renal insufficiency.
Combined liver-kidney grafts have been performed in a few cases. Prognosis is usually good: late hepatic and renal
complications may occur, however, with adapted management, patients have almost normal life span.
Disease name and synonyms: Glucose-6-phosphatase deficiency or G6P deficiency or glycogen storage disease
type I or GSDI or type I glycogenosis or Von Gierke disease or Hepatorenal glycogenosis.
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Glycogen storage disease ty p eI( G S D I )i sag r o u po f
rare inherited diseases resulting from a defect in the glu-
cose-6-phosphatase (G6Pase) system which has a key
role in glucose homeostasis as it is required for the
hydrolysis of glucose-6-phosphate (G6P) into glucose
and inorganic phosphate (Pi). The main diagnostic cri-
teria are: hepatomegaly, fast-induced hypoglycemia with
hyperlactacidemia, and hyperlipidemia. Two main sub-
types are unambiguously recognized: GSD type Ia
(GSDIa) due to a defect of the catalytic unit G6Pase-
alpha (or G6PC), and GSD type Ib (GSDIb) due to a
defect of the glucose-6-phosphate translocase (or G6PT)
[1,2]. The existence of other types (type Ic and type Id)
has not been confirmed [3,4].
Epidemiology
GSDI has an estimated annual incidence of around 1/
100,000 births, representing approximately 30% of hepa-
tic GSD and with GSDIa being the most frequent type
(about 80% of the GSDI patients)[1]. GSDIa is particu-
larly common in the Ashkenazi Jewish population, in
which the carrier frequency for the p.R83C allele was
found to be 1.4%, predicting a prevalence five times
higher than in the general Caucasian population [5].
Clinical description [1,2,6]
GSDI patients may present with fast-induced hypogly-
cemia (sometimes occurring rapidly in about 2 to 2 and
a half hours after a meal) and hyperlactacidemia in the
neonatal period. More commonly, the first symptom is
the presence of a protruded abdomen due to marked
hepatomegaly around 3 months of age, though in some
cases the liver may already be enlarged at birth. The
liver size gradually increases and the lower border may
reach below the umbilicus. It must be stressed that the
hepatomegaly may be missed on physical examination,
as the liver is soft. Hepatocellular adenomas are usually
asymptomatic and physical examination is rarely contri-
butive, except in very rare cases when adenomas are
superficial. Fasting tolerance is very limited: hypoglyce-
mia, which may cause convulsions, and lactic acidemia,
account for the initial gravity of the disease. In some
cases, the hypoglycemia may be less symptomatic since
lactate may be used as a cerebral metabolic fuel. The
other biological hallmarks are hyperlipemia and hyper-
uricemia. The full-cheeked, round “doll like” face, and a
protruding abdomen contrast with the thin limbs.
Growth delay and late onset of puberty [2,7] are very
frequent signs, which can be improved by good meta-
bolic control [8]. Osteopenia [9] is commonly found and
it has been suggested that the subclinical muscle weak-
ness could also contribute to the low bone mass [10].
Chronic acidosis and hypertriglyceridemia also play an
important role in the development of osteopenia. Kid-
neys are enlarged. Platelet dysfunction, which is related
to dyslipidemia, explains the tendency for ecchymoses
and bleeding. Anemia is commonly found. Intermittent
diarrhea occurs in a number of patients. Ovarian cysts
have also been reported. Recently, an increased preva-
lence of hypothyroidism (GSDIa and GSDIb) and thyr-
oid autoimmunity (GSDIb) has been reported [11].
Long-term complications [12-14] can be delayed by
good metabolic control.
The development of hepatocellular adenomas (HCA)
is a well-known complication. They are usually detected
between the second and the third decades of life, and
their frequencies range from 16 to 75% and are equal in
both sexes, [2]. The diagnosis is rarely based on physical
examination, except when superficial adenomas develop,
making the liver surface uneven [15-18]. Usually, liver
ultrasound, CT scan or MRI allow the diagnosis and
regular follow-up is thus necessary During the first ten
years, liver ultrasound should be performed once a year.
S i n c et h ea g eo f1 0 ,l i v e rM R Im a yb ep r o p o s e de a c h
year. Specific MRI patterns, related to diffuse fat reparti-
tion and sinusoid dilatation have been aasociated with
HNF-1a - mutated adenomas and inflammatory adeno-
mas, respectively [19]. Furthermore, chemical-shift MRI
has been useful in discriminating increased liver echo-
genicity in GSDs [20]. MRI also allows the quantifica-
tion of hepatic steatosis. Should hepatic lesions be
detected, the follow-up must be intensified, and liver
MRI should be proposed every 6 months, sometimes
combined with ultrasound examinations if MRI is more
difficult to organize. CT scan may be useful, should a
surgical resection of adenomas be plannned.
Renal complications start with silent glomerular hyper-
filtration before the development of microalbuminuria
then proteinuria, which can lead to renal failure [2].
Hypercalciuria is a consequence of renal distal tubular
dysfunction and may contribute to renal calculi and/or
nephrocalcinosis and osteopenia. Hypocitraturia has
been reported as a risk factor for nephrocalcinosis
[21,22]. Oxidative stress has also been reported as a
mechanism underlying GSD-Ia nephropathy [23]. When
microalbuminuria has been detected and confirmed,
treatment with angiotensin converting enzyme inhibitors
must be started without delay [24]
Hyperuricemia [25] must be treated because it can
lead to gout and, above all, it participates (together with
hypocitraturia) in the constitution of stones, nephrocal-
cinosis and renal failure [2].
Severe hypertriglyceridemia seems to increase the risk
of pancreatitis [26] but, to date, the risks of athero-
sclerosis and early cardiovascular complications do not
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study of 28 patients with GSDI (mean age 23 years)
reported arterial dysfunction which was characterized by
increased carotid intima media thickness and a higher
augmentation index measured by radial artery tonometry
[30].
Pulmonary hypertension is a very rare complication
and its prognosis is very poor [15,31,32]. Its physio-
pathology is not well known; abnormalities in the plate-
let metabolism of serotonin have been suspected [32].
GSDIb patients
In addition to these signs that characterize GSDIa,
GSDIb patients generally present with neutropenia that
appears not to be due to a defect in bone marrow pro-
duction. Neutrophils and/or monocytes are functionally
abnormal, showing decreases in respiratory burst and
motility in response to stimuli [3,4]. This dysfunction is
responsible for recurrent infections, oral and intestinal
mucosal ulcerations and inflammatory intestinal diseases
suggestive of Crohn’s disease [33-35]. This condition has
occurred in over 77% of patients with GSDIb by adult-
hood [33]. The development of diarrhea, persistent
abdominal pain, unexplained fever, gastrointestinal
bleeding, perianal lesions should lead to further evalua-
tion. Colonoscopy must be performed; should it be
negative, endoscopic evaluation of the small bowel has
to be considered. [36]. Recently, elevated levels of anti-
bacterial flagellin antibodies (anti-CBir1) have been
detected in the serum of 17/19 GSDIb patients [37]. As
these antibodies have been associated with Crohn dis-
ease in the general population, these data are interesting.
However, in this study, the antibody did not discrimi-
nate patients with and without inflammatory bowel dis-
ease and long-term follow-up is necessary to know
whether these antibodies can predict the occurrence of
intestinal inflammation [37].
A few of the reported patients (about 10%) did not
present with neutropenia and/or neutrophil dysfunction
[38-40]. Interestingly, one of these patients [38] had a
mutation that only partially affected the activity of the
transporter [41]. In contrast, neutropenia is very rare in
GSDIa patients [42]. Splenomegaly, which is very rarely
found in GSDIa patients, was reported (together with
hepatomegaly) more frequently in GSDIb patients [2,43],
specially in those receiving treatments with G-CSF.
Pregnancy
Fertility is normal in GSDI patients and several pregnan-
cies have been reported in affected women. Close moni-
toring of these pregnancies is required due to the risk of
exacerbating the renal problems, of the enhanced danger
of hemorrhages and of the need to provide satisfying
metabolic control for the fetus [44]. In GSDIa mothers,
most neonates have been delivered by cesarean section
[45]. In GSDIb mothers, five successful pregnancies in
three patients have been recently reported [46]. There
were no major complications related to neutropenia
except for oral ulcers and all neonates were delivered
vaginally.
Developping a strategy for an optimal management of
contraception in GSD I women is crucial. Ethynyloestra-
diol should be avoided because of a link with hepatic
adenomas and is contraindicated in patients with hyper-
triglyceridemia and hypercholesterolemia. Blockage of
ovulation can be achieved using high doses of progesto-
gen alone, administered from the 5
th to the 25
th day of
the cycle. Another possibility is based on daily adminis-
trations of low doses of progestogen [44]. Mechanical
contraception using intra-uterine device is controversial
in such patients.
Etiology
Enzyme deficit
GSDI was first described by von Gierke in 1929. In
1952, Cori and Cori showed that the disease (called
GSDIa) was caused by a deficit in G6Pase, an enzyme
expressed mainly in the liver and kidney and, to a lesser
degree, in the intestine. Subsequently, it was found that
some patients are not deficient in G6Pase, even though
a number of functional tests demonstrated their inability
to degrade G6P in vivo:t h i sc o n d i t i o nw a sc a l l e d
GSDIb. To explain this defect, Arion et al [47] hypothe-
sized that G6P hydrolysis required the participation of
several proteins located in the endoplasmic reticulum
(ER) membrane: a catalytic unit (G6Pase) capable of
hydrolyzing several phosphate esters (G6P, mannose-6-
phosphate, carbamylphosphate and pyrophosphate) and
a G6P-specific bidirectional translocase (G6PT), which
would assure its entry into the lumen of the endoplas-
mic reticulum, where G6Pase exerts its action. Unlike
G6Pase, G6PT is expressed ubiquitously. G6Pase and
G6PT were found to be co-dependent as G6Pase activity
is required for efficient transport of G6P into the ER
lumen [48].
On the basis of kinetic studies, Arion et al. [47] pro-
posed in 1980 a multicomponent model with specific
transmembrane transporter proteins for G6P (T1), phos-
phate, pyrophosphate and carbamylphosphate (T2) and
glucose (T3). Nordlie et al [49] described a patient with
GSDIc who had a deficit in the bidirectional translocase
(T2) which allows phosphate resulting from G6P hydro-
lysis to leave the endoplasmic reticulum. The existence
of GSD type Ic was discussed when mutations in the
gene encoding G6PT were identified in most of these
patients [50]. However, no mutation was found in the
gene encoding G6PT in the patient originally described
by Nordlie [50,51], thereby suggesting that another
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patient was affected by a different disorder. The hypoth-
esis that the gene coding for a microsomal phosphate
transporter (NPT4) was mutated in GSDIc patients
devoid of mutations in the G6PT gene could not be
confirmed [52]. Recently, it has been demonstrated that
G6PT is an organophosphate:Pi antiporter transporting
G6P into the ER lumen and Pi out. This supports that
GSDIb and GSDIc which are deficient in the same
G6PT gene represent a single disease [53].
The existence of GSD type Id, attributed to a deficit in
translocase (T3) has never been proven and the hypoth-
esis that the glucose transporter GLUT7 could be
involved was ruled out when mutations were identified
in the gene encoding G6PT [50].
The G6Pase deficient in GSDIa was subsequently
renamed G6Pase-alpha as another G6P hydrolase named
G6Pase-beta (or G6PC3) has been identified. G6Pase-
beta is ubiquitously expressed and can form a complex
with G6PT in non gluconeogenic organs, which could
explain why endogenous glucose is still produced in
GSDIa patients [6,54]. However, Wang et al [55] showed
that the deletion of the gene encoding the G6Pase-beta
in mice does not result in hypoglycemia and that the
phenotype of knock-out mice is mild.
The role of G6PT, in addition to that in the glucose-
6-phosphatase system, has not yet been fully elucidated.
A role in the differentiation of neutrophils has been sug-
gested [56] and studies in mice model have shown that
G6PT is also an important immunomodulatory protein
[57]. Recent studies provided evidence that neutrophil
homeostasis and function is linked to the endogenous
glucose production via the G6PT/G6Pase-beta complex.
G6PT deficient or G6Pase-beta deficient neutrophils are
unable to produce endogenous glucose and would mani-
fest enhanced ER stress and apoptosis, which could con-
tribute to neutrophil dysfunction in GSDIb patients
[58]. Cheung et al [59] showed that mice lacking the
G6Pase-beta had impaired neutrophil activity and
increased susceptibility to bacterial infection. G6Pase-
beta deficiency has been recently identified in patients
presenting a severe congenital neutropenia syndrome
[60].
Metabolic alterations
In GSDI, the fasting hypoglycemia results from the
blockage of the last step of glycogenolysis and gluconeo-
genesis. However, a few patients show an unexpected
tolerance to fasting [61].
Hyperlactacidemia and glycogen storage are due to
excess G6P which cannot be metabolized to glucose.
Thus, galactose, fructose and glycerol will not correct
hypoglycemia and will contribute to hyperlactacidemia.
Hyperlipidemia is a result of both increased synthesis
from excess of acetyl-coenzyme A via malonyl-coen-
zyme A (the first step of fatty acid synthesis), and
decreased lipid serum clearance, though mechanisms of
both hyperlipidemia and liver steatosis are not comple-
tely understood [62]. Accumulation of fats in the liver
significantly contributes to the hepatomegaly.
Increased malonyl-coenzyme A inhibits carnitine pal-
mytoyltransferase I, resulting in reduced ketone produc-
tion and increased dicarboxylic aciduria. Hyperuricemia
[1,6] is caused by both decreased renal clearance (lactate
competes with uric acid) and increased synthesis
(decreased intrahepatic phosphate concentration stimu-
lates the degradation pathway of adenine nucleotides).
Mechanisms underlying the development of
hepatocellular adenomas
The mechanisms underlying the development of HCAs
are still not completely elucidated. However, a new clas-
sification of HCA and a better knowledge of their rela-
tionship with hepatocellular carcinoma was proposed by
Zucman Rossi et al [63]. A recent study has reported
chromosomal and genetic alterations in HCAs asso-
ciated with GSDIa: simultaneous gain of 6p and loss of
6q, association of larger HCAs with chromosome 6
aberrations, reduced expression of IGF2R and LATS1
(candidate tumour suppressor genes) at 6q in more than
50% of HCAs associated with GSDIa [64]. The activa-
tion of b-catenin has been reported to be an important
risk factor for malignant degeneration [63]. To date, the
presence of activated b-catenin has been reported in 3
GSDIa HCAs, among which one was associated with a
carcinoma.
The role of metabolic control in adenomas formation
has also been discussed. In a case-control retrospective
study, no significant differences in metabolic balance
could be detected between GSDI patients who devel-
oped adenomas and those who did not [65].
Another mechanism could involve serum cytokines.
Kim et al [66] have reported that GSDIa mice exhibit a
persistent increase in peripheral blood neutrophil counts
along with elevated levels of granulocyte colony stimu-
lating factor (G-CSF) and cytokine-induced neutrophil
chemoattractant. The authors suggest that there is a
progressive low level of immune challenge since there is
a long-term damage to the liver in GSDI patients
despite dietary controls [66].
Refractory iron deficiency anemia
Severe refractory iron deficiency anemia has been
reported in GSDIa patients with hepatocellular adeno-
mas, that is alleviated with either adenoma resection or
liver transplantation [67,68]. The role of hepcidin, a pro-
peptide that is converted in three mature peptides and
which limit both release of iron from macrophages and
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levels of hepcidin mRNA expression were found in the
adenomas of anemic GSDIa patients whereas hepcidin
mRNA expression was decreased in the unaffected liver
[ 6 8 ] .T h eu p r e g u l a t e dp r o d u c t i o no fh e p c i d i ni na d e n o -
mas would result in the dysregulation of the iron utiliza-
tion cycle in GSDIa patients [68]. More studies are
required to continue to shed some light on the precise
mechanisms of anemia in such patients.
Mutations and genotype/phenotype correlations
GSDIa
Human G6Pase gene (G6PC) was isolated by Lei et al.
[69]. The gene has been localized to chromosome 17 at
17q21, spans 12.5 kb, includes 5 exons and codes for a
highly hydrophobic protein of 357 amino acids contain-
ing 9 transmembrane helixes. Its promoter contains sev-
eral response elements for glucocorticoids, cyclic AMP
and insulin, and is regulated by hepatocyte nuclear fac-
tors that control its expression [70].
Over 550 unrelated patients affected with GSDIa have
been studied worldwide and more than 85 mutations
(Human Gene Mutation Database; http://www.hgmd.cf.
ac.uk, [71]) have been identified. The majority are mis-
sense mutations (64%) [38,41,72-74] and all of them are
small gene alterations. A few alleles could not be identi-
fied. Only some of the mutations have a significant fre-
quency [75]:
- in the Caucasian population, p.R83C and p.Q347X
are found in 33% and 18% of the GSD Ia alleles,
respectively.
- in Jewish patients, p.R83C is particularly frequent
(98% of the alleles) and p.Q347X is found in the
remaining alleles (2%).
- in Hispanic Americans, the c.380_381insTA muta-
tion represents about half of the alleles.
- in Japanese patients, the p.Q347X and p.R83C
mutations have never been found, p.R83H is very
rare, but the silent nucleotide change c.648G > T,
responsible for the deletion of 91 nucleotides in
exon 5 in the cDNA, is present in 91% of the GSDIa
alleles in this population.
- in Chinese patients, c.648G > T is also frequent
(54% of the alleles). The p.Q347X mutation has
never been found and p.R83C only once, while p.
R83H is present in 26% of the mutated alleles.
- in Korean patients, c.648G > T is also the most
frequent mutation (75%).
- in Tunisian patients, p.R83C and p.R170Q accounts
for 67% and 28% of the alleles respectively [76].
The structure and function of fifty missense mutations
and the in-frame deletion p.F327del have been studied
[73,77]. The 5 active site mutations (including the p.
R83C/H mutations), 23 of the 32 helical mutations and
8 of the 14 non helical mutations abolish completely the
activity (altering protein stability and/or catalytic capa-
city). The remaining studied missense mutations are
associated with some residual activity. The results of
this study [77] should help facilitating genotype-pheno-
type delineation, at least for patients homozygous for a
studied mutation. A Japanese patient homozygous for
the non helical p.P257L mutation had a very mild phe-
notype, in accordance with expression study, and experi-
enced no hypoglycemic episodes. The clinical phenotype
of patients carrying these “mild” mutations should be
precisely documented in order to try to determine the
minimal G6Pase activity required for avoiding hypogly-
cemic episodes. The c.648G > T homozygous status was
associated with a milder phenotype with respect to
hypoglycemic events [42] but other genetic and/or
acquired factors may have influence on a possibly
increased risk for hepatocellular carcinoma [78]. Inter-
e s t i n g l y ,i tw a sf o u n dt h a tp . G 1 8 8 Rh o m o z y g o s i t yc o n -
fers an atypical GSDIb phenotype with neutropenia and
recurrent infections [79].
GSDIb
The human G6PT gene (SLC37A4) has been localized to
chromosome 11 at 11q23 [80], spans 4.5 kb, contains 9
exons and codes for a highly hydrophobic protein con-
taining 10 transmembrane domains [81,82]. Unlike
G6Pase, G6PT is expressed in many tissues and tissue-
specific splicing is responsible for several variants, the
significance of which has not yet been elucidated [82]. It
is highly expressed in the liver, pancreas, kidney and
hematopoietic progenitor cells [54]. In the liver and leu-
cocytes, exon 7 is not expressed. SLC37A4 gene expres-
sion is regulated, like that of G6PC,b yg l u c o s e ,i n s u l i n
and cyclic AMP [70].
Over 160 patients have been studied worldwide to
date [38,42,49,80-82] and more than 81 mutations have
been identified (Human Gene Mutation Database;
http://www.hgmd.cf.ac.uk, [71]).
All are small size gene alterations except one case of
large deletion [83]. Most of them are missense muta-
tions (40%). No SLC37A4 gene mutations have been
found in exon 7, the 5’ part of exon 1 and the 3’ portion
of exon 9, which are not expressed in the liver tran-
script. Molecular heterogeneity is extreme but several
mutations predominate and vary according to the popu-
lation: c.1042_1043delCT and p.G339C are the most
common in the Caucasian population, where they repre-
sent nearly half of the G6PT alleles, and the p.W118R
mutation is present in nearly 40% of the Japanese G6PT
alleles [42].
Af u n c t i o n a la s s a yf o rG 6 Pt r a n s p o r th a sb e e nd e v e l -
oped and used to characterize 30 of the mutations: 20
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10 retained residual activity including the p.G339C
mutation [84]. Additionally, a three dimensional struc-
tural model was built by homology modelling in order
to predict in silico the effect of mutations [85]. No cor-
relation was found between individual mutations and
the absence of neutropenia, bacterial infections and sys-
temic complications [30,86].
Diagnosis
Biochemical methods of diagnosis
Biological hallmarks: fasting tolerance is poor and fast-
ing blood analyses reveal hypoglycemia, hyperlactacide-
mia, hypertriglyceridemia, hypercholesterolemia and, in
many cases, hyperuricemia.
Functional tests show the absence of a glycemic
response and an aggravation of hyperlactacidemia after
injection of glucagon (1 mg/m
2 of body surface) in a
fasting patient or 2 hours after a meal rich in carbohy-
drates. Galactose injection (1 g/kg) neither induces
hyperglycemia nor corrects the hypoglycemia.
Other biological abnormalities include hypoacetonemia
hypoinsulinemia and hyperglucagonemia. Additionally,
marked elevation of serum biotinidase activity has been
reported in GSDIa patients [87].
Study of the G6Pase system in a liver biopsy [88]
The biochemical diagnosis of GSDI requires a liver
biopsy (ideally fresh, not frozen), sufficiently large to
enable the analysis of the different constituents of the
G6Pase system. A homogenate is prepared under condi-
tions maintaining or not microsomal membrane integ-
rity. Hydrolytic activity is measured using several
substrates: mannose-6-phosphate (to evaluate microso-
mal membrane integrity), G6P and pyrophosphate. In
type Ia, hydrolytic activity is defective, regardless of the
substrate used and the status of microsomal membranes.
In type Ib, G6P hydrolysis is defective when microsomal
membranes are intact [89].
No biochemical phenotype-clinical phenotype correla-
tions could be established based on the results of resi-
dual activity and glycogen storage in the liver.
Histopathological findings
Histology of the liver shows glycogen and fat-induced
hepatocytic distension. Fibrosis may also be present in
some patients.
Molecular studies
Complete sequencing of the G6PC (GSDIa) and
SLC374A (GSDIb) genes allows diagnosis in nearly all
patients with evocative clinical and biochemical signs of
GSDI, thereby eliminating the need for a liver biopsy.
Differential diagnosis
Nearly all cases are diagnosed in infancy. A limited
number of clinical and biological parameters allow the
diagnosis: marked and soft hepatomegaly associated
with hypoglycemic episodes and elevated fasting blood
lactate concentration decreasing after a carbohydrate
rich meal or a glucose tolerance test are indicative of
GSDI. Diagnosis may be more difficult in older patients,
especially in the few patients who present an unusual
prolonged tolerance to fasting [6,90].
Among other gluconeogenesis disorders, fructose-1, 6
diphosphatase deficiency can be discussed in some
cases. However, in this disease, the tolerance to fasting
is much longer (8 to 10 hours) than it is in GSDI, and
the liver is not as enlarged.
Other types of GSD may be evoked. GSDIII (amylo-1-
6-glucosidase deficiency) may be clinically similar in
infancy but hypoglycemia is usually not as severe as in
type I because gluconeogenesis is intact and phosphory-
lase is still able to metabolize peripheral branches of gly-
cogen. In GSDIII, lactatemia at fast and uric acid are
typically normal, and liver transaminases levels are
higher than in GSDI. GSD type VI (hepatic phosphory-
lase deficiency) or type IX (hepatic phosphorylase b
kinase deficiency) should be also evoked as a severe pre-
sentation of these diseases may exist.
Primary liver tumors and Pepper syndrome (hepatic
metastases of neuroblastoma) may be evoked but are
easily ruled out through clinical and ultrasound data.
Genetic counseling
The disease is transmitted as an autosomal recessive
trait. Both parents of an affected child are heterozygotes.
The risk of recurrence is 25%, at each pregnancy. Identi-
fication of both mutations in the patient enables the
diagnosis of potential heterozygotes in the family.
Prenatal diagnosis
The good response of most patients to dietary control
has rendered prenatal testing relatively rare. Nonetheless,
some children respond poorly to the diet and will require
a liver transplant. In addition, GSDIb is often accompa-
nied by severe infections and inflammatory bowel disease.
Before the discovery of the gene, prenatal diagnosis of
GSDIa required a fetal liver biopsy obtained late in
pregnancy, and was subject to diagnostic errors. Prenatal
diagnosis of GSDIb had never been achieved.
To date, molecular studies have made prenatal diagno-
sis of GSDIa and GSDIb easy to perform when the
familial mutations have been identified [91-93]. Fetal
DNA may be extracted from chorionic villi or from
amniotic fluid cells.
Froissart et al. Orphanet Journal of Rare Diseases 2011, 6:27
http://www.ojrd.com/content/6/1/27
Page 6 of 12Management including treatment [1,2,6,30,94]
Detailed guidelines for patient’s management based on
the data of the European Study on Glycogen Storage
Disease type I have been provided [95].
Dietary treatment
Treatment aims at preventing hypoglycemia in order to
avoid neurological involvement and long-term complica-
tions (hepatic, renal, etc.) and to assure normal growth.
Treatment is essentially dietary and consists of fre-
quent meals, continuous nocturnal nasogastric drip
feeding, ingestion of slow-absorption carbohydrates
(uncooked starch: [96]), and restricted intakes of both
fructose and galactose which can aggravate
hyperlactacidemia.
Daily caloric intake must be monitored: insufficient
intake does not correct the metabolic disorder (hypogly-
cemia, hyperlactacidemia and hyperuricemia) and leads
to retarded growth, whereas excessive intake increases
the glycogen overload, hepatomegaly and hyperlipide-
mia, and causes obesity. The diet must provide 60-65%
of total caloric intake from carbohydrates, 10-15% from
proteins and the reminder from fat.
Until 12 months, frequent meals (5 meals per day) and
continuous nocturnal feeding via a nasogastric tube,
providing 6-8 mg of glucose/kg/min, are recommended.
However, continuous nocturnal feeding may be, in some
cases replaced by nocturnal meals.
After 1 year, uncooked cornstarch (which may be
introduced from 9 to 12 months of age, with progressive
increase of doses) can, in some patients, replace the
continuous nocturnal feeding at the initial dose of 0.5 g/
kg then slowly increased to 1 g/kg every 4 hours. As the
child grows older, the cornstarch regimen can be chan-
ged to the dose of 1.5-2.0 g/kg every 6 hours.
Another therapeutic regimen may be proposed and
discussed for cornstarch which can be started during
infancy, and given between meals or before bed so as
not to interfere with appetite at meal time (94). Recom-
mendations for dosing are: 1.6 g/kg body weight every 4
hours for infants, 1.7-2.5 g/kg body weight every 6
hours for young children through puberty, and 1.7-2.5
g/kg body weight given before bed time for adults. A
novel and modified starch is being tested in GSD
patients. To date, it seems that this new starch might
allow, in some patients, longer duration of euglycemia
and better short-term metabolic control [97,98]. This
starch is allowed in several countries (United Kingdom,
Netherlands, Germany).
In adults, the cornstarch dose and the intake interval
can be increased. However, several adults stop taking
cornstarch, even though they are encouraged to
continue.
Treatment efficacy is evaluated by monitoring clinical
(growth curve, body mass index, importance of hepato-
megaly, blood pressure) and biological parameters. The
preprandial glycemia must be above 3.5 mmol/L and
adjusted to the actual urinary lactate excretion, which
must be below 0.06 mmol/mmol creatinine in 12 hours
urine samples (night and day). Blood lactate monitoring,
when available, may be useful for supplementing glucose
monitoring [99]. Hyperlactatemia causes acute clinical
deterioration whereas chronic hyperlactatemia has been
associated with long-term complications of GSDI. The
main use of lactate monitoring is during intercurrent ill-
ness, when the rapid development of lactic acidosis is
very likely. In such situations, the use of a portable lac-
tate meter seems to be a valuable tool [99]. Triglyceride-
mia, cholesterolemia, uricemia, blood gazes, proteinuria
and complete blood cell count should be measured at
each outpatient visit.
Portocaval shunts were recommended in the past but
accorded very limited clinical benefit and have been
abandoned, since 1984 [4].
Surgery requires special care [4] in these patients at
increased risk of hemorrhages and metabolic imbalances
(hypoglycemia and hyperlactacidemia): glycemia must be
maintained (perfusions of 10% glucose before, during
and after the intervention) and solutions containing lac-
tate should be avoided (Ringer’s, for example). Corticos-
teroids may be discussed for a short period even though
their use is usually contraindicated., and careful follow-
up and correction of hemostasis abnormalities are
mandatory.
Therapeutic adjuvants include vitamin supplements
(vitamins D and B1, etc.), calcium (considering limited
milk intake), iron in case of anemia (after excluding
other causes) and allopurinol when hyperuricemia is
present. If permanent microalbuminuria is present,
treatment with angiotensin-converting enzyme (ACE)
inhibitor is started with the aim of preventing renal
complications [24], and additional blood pressure lower-
ing drugs may be added if blood pressure remains ele-
vated. Should the patient become pregnant, ACE
inhibitors must be stopped at once. Hyperlipemia only
responds partially to dietary treatment, but triglyceride
lowering drugs are not indicated if the level remains
below 10 mmol/L. Cholesterol lowering drugs are not
indicated in young patients because of the low risk of
atherogenicity.
For GSD type Ib, granulocyte colony-stimulating fac-
tor (G-CSF) is able to correct the neutropenia, reduces
the severity of bacterial infections and attenuates inflam-
matory intestinal disease [33,100]. Chronic G-CSF ther-
apy may consist in two to three weekly injections, the
average dose per injection being about 5 μg/kg body
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untoward effects may develop such as splenomegaly,
thrombocytopenia, renal carcinoma [101]. Should pegy-
lated G-CSF be used, other side effects must be known
such as the occurrence of Sweet syndrome in one
patient [102], respiratory distress and sudden death in
another patient [101]. Careful monitoring of the
patient’s spleen size, total blood cell counts and bone
density is recommended in GSD Ib patients receiving
G-CSF [35,100].
Colitis is often treated with success using a combina-
tion of G-CSF and 5-aminosalicylic acid derivatives
[36,100]. However, in a few cases, this treatment fails
and other therapeutic approaches must be discussed.
Corticosteroids are generally avoided in such situations,
owing to steroid-induced glycogenolysis and the possibi-
lity of lactic acidosis and hyperlipidemia., Immunosup-
p r e s s i v ed r u g ss u c ha sm e t h o trexate, azathioprine and
6-mercaptopurine carry the ri s ko fe x c e s s i v ei m m u n o -
suppression and worsening neutropenia in GSD Ib
patients. Adalimumab, a fully humanized monoclonal
anti-TNF has been reported to be successful in one GS
Ib patient with inflammatory bowel disease who was
refractory to usual medical treatment [36]. Fecal alpha-1
antitrypsin must be monitored for evaluation of inflam-
matory bowel disease in GSDIb [38].
Detection and follow-up of complications
Even though the risk of malignant transformation of
adenomas into hepatocellular carcinomas appeared to
be low [2,16,17], ie no malignant transformation had
been reported in the European retrospective study, some
recent reports suggested that the older the patients get,
the more important the risk of transformation becomes
[103]. The management of adenomas remains empirical;
it may be expectant or surgical. Clinically, should
abdominal pains occur and require major painkillers to
be controlled, malignant transformation must be sus-
pected, even though these manifestations are not speci-
fic. Biological markers (serum a fetoprotein and ACE)
are not predictive of malignant transformation. Liver CT
scan and MRI may be useful in such cases, even though
further evaluations are needed. Surgical resection of
hepatic adenomas is feasible. Previous reports have
noted frequent haemorragic problems [104], but such
complications may be avoided, provided meticulous
metabolic control is obtained before surgery (personal
data).
If dietary control fails or hepatic adenomas undergo
malignant transformation, treatment of complications
consists of liver transplantation [105]. Liver grafting cor-
rects the hypoglycemia and the other biochemical
anomalies but the correction of neutropenia is not con-
stant [106,107]. It has not been proven that it can
prevent renal involvement, which may even be worsened
by the immunosuppressive therapy. However, there is
limited experience of liver transplantation for GSDI
given the rarity of the disease. Chronic allograft rejec-
tion, post-transfusion hepatitis C infection, renal failure,
gouty arthritis, and portal vein thrombosis requiring re-
transplantation have been reported [67]. The current lit-
erature shows that satisfactory medium-term outcomes
can be achieved in GSD I patients (review in [67]). Simi-
lar data have been reported regarding living donor liver
transplantation in such patients [108]. As pointed out by
Davis and Weinstein (2008), the risks and benefits of
liver transplantation should be carefully evaluated and
t h el a t t e rs h o u l do n l yb ep e r f o r m e dw h e nt h e r er i s kf o r
hepatocellular carcinoma or liver dysfunction is high
[109]. Liver cell transplantation could provide a less
invasive approach in the future [110]. It has been
reported in a GSDIb patient with marked improvement
up to 250 days following transplantation; however, long-
term results are still unknown and the use of immuno-
suppressive agents is mandatory [111].
Bone marrow transplantation has been reported in
one GSDIb patient who had life-threatening complica-
tions related to neutropenia and thrombocytopenia. It
resulted in improved metabolic control and reduction of
inflammatory bowel disease-related symptoms [112].
Kidney transplantation, performed in case of severe
renal failure, does not correct hypoglycemia [103].
Should grafting be indicated, combined liver-kidney
graft has been discussed when renal function is already
compromised and successfully performed in a few cases
[113,114].
Prognosis [2,6,8]
Efficient and early dietary treatment has led to reduced
mortality and morbidity, and most patients are able to
live a fairly normal life. If normoglycemia is maintained,
metabolic abnormalities and clinical parameters improve
in most patients, though hyperlipidemia persists. The
incidence of adenomas seems to be lower but renal dis-
ease cannot be completely avoided, even in good
responders. Some patients do not respond well, continue
to be short and may require liver or dual kidney/liver
transplant (with the mortality and morbidity associated
with these procedures). In GSDIb, good metabolic con-
trol may be more difficult to obtain because of recurrent
serious infections and inflammatory bowel disease.
Unresolved questions and ongoing research
[3,4,17,115]
The nature of the interactions between G6Pase and
G6PT, and the functions of G6PT other than in G6P
transport, remain incompletely resolved. The mechan-
isms by which G6PT deficiency affects neutrophils
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tion via the G6PT/G6Pase-beta complex in normal neu-
trophil function remains to be elucidated. Other
unsolved questions include the source of endogenous
glucose production which increases with age leading to
a better fasting tolerance, the etiology of most complica-
tions (growth retardation, liver adenomas, renal involve-
ment, etc.) and the management of liver adenomas in
the absence of clear-cut criterion to detect their early
malignant transformation. Animal models should pro-
vide answers to these questions and should improve our
understanding of the pathophysiology of these diseases.
T h er o l eo fG 6 P a s ei nt h es m a l li n t e s t i n ei nt h ec o n -
trol of glucose homeostasis has been well established
[116]. Gluconeogenesis in the small intestine plays an
important role in glucose balance. These data have been
confirmed in the liver-specific G6Pase gene knock-out
mice who do not exhibit hypoglycemia due to their
intestinal (and renal) G6Pase activity [117]. In connec-
tion with this, more attention should be paid to intest-
inal manifestations in GSD I patients.
The efficacy of gene therapy has been studied in
mouse and dog models. Adeno-associated virus (AAV)
mediated therapy delivers the transgene to the liver of
GSDIa mice, achieving long term correction [118]. In
dogs, a significant correction of the GSDIa phenotype
has been reported in two animals, using AAV mediated
gene tranfer [119]. Only a few experiments were per-
formed in the GSDIb model, but an improvement of
metabolic profile and myeloid function was reported
[120].
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